Download PDF
Semin Respir Crit Care Med 2006; 27(2): 117-127
DOI: 10.1055/s-2006-939514
Copyright © 2006 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

The Eosinophil: The Cell and Its Weapons, the Cytokines, Its Locations

Harsha H. Kariyawasam1 , 2 , Douglas S. Robinson1 , 2
  • 1Allergy and Clinical Immunology, National Heart and Lung Institute, London, United Kingdom
  • 2Leukocyte Biology Section, Faculty of Medicine, Imperial College London, London, United Kingdom
Further Information

Publication History

Publication Date:
13 April 2006 (online)

    Permissions and Reprints

ABSTRACT

Although the functional role of eosinophils is primarily considered to be host defense against parasitic infection, current studies indicate that this complex cell is ideally adapted for other roles that may involve immune modulation and tissue repair. The eosinophil is an important source of basic proteins, lipid mediators, cytokines, and growth factors. In disease states, eosinophil mobilization from the marrow and circulation can be very rapid yet highly organized and cell selective, particularly in response to interleukin (IL) 5 and eotaxin. Such elaborate recruitment is regulated by a series of interactions by eosinophil receptors and the endothelium and extracellular matrix ligands. Several priming mechanisms activate the eosinophils during this recruitment process so that the cell arrives at its tissue destination prepared for immediate action and prolonged tissue survival. Degranulation is strictly controlled and allows the cell to differentially release its contents in an ordered manner. This is essential to prevent injury to tissue during migration. Therapy is still limited for eosinophil-driven diseases, but intervention at the key events that govern eosinophil recruitment and effector function may be the way forward.

KEYWORDS

Eosinophils - host defense - immunomodulation

REFERENCES

  • 1 Steinbach K H, Schick P, Trepel F et al.. Estimation of kinetic parameters of neutrophilic, eosinophilic, and basophilic granulocytes in human blood.  Blut. 1979;  39(1) 27-38
    PubMedGoogle Scholar
  • 2 Sokol R J, James N T, Wales J, Hudson G. Morphometry of eosinophils in human blood.  Acta Anat (Basel). 1987;  129(3) 211-213
    PubMedGoogle Scholar
  • 3 Ackerman S J, Liu L, Kwatia M A et al.. Charcot-Leyden crystal protein (galectin-10) is not a dual function galactin with lysophospholipase activity but binds a lysophospholipase inhibitor in a novel structural fashion.  J Biol Chem. 2002;  277(17) 14859-14868
    CrossrefPubMedGoogle Scholar
  • 4 Dvorak A M, Letourneau L, Login G R, Weller P F, Ackerman S J. Ultrastructural localization of the Charcot-Leyden crystal protein (lysophospholipase) to a distinct crystalloid-free granule population in mature human eosinophils.  Blood. 1988;  72(1) 150-158
    PubMedGoogle Scholar
  • 5 Menzies-Gow A, Flood-Page P, Sehmi R et al.. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics.  J Allergy Clin Immunol. 2003;  111(4) 714-719
    CrossrefPubMedGoogle Scholar
  • 6 Kopf M, Brombacher F, Hodgkin P D et al.. IL-5-deficient mice have a developmental defect in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses.  Immunity. 1996;  4(1) 15-24
    CrossrefPubMedGoogle Scholar
  • 7 Takamoto M, Ovington K S, Behm C A, Sugane K, Young I G, Matthaei K I. Eosinophilia, parasite burden and lung damage in Toxocara canis infection in C57Bl/6 mice genetically deficient in IL-5.  Immunology. 1997;  90(4) 511-517
    CrossrefPubMedGoogle Scholar
  • 8 Dent L A, Strath M, Mellor A L, Sanderson C J. Eosinophilia in transgenic mice expressing interleukin 5.  J Exp Med. 1990;  172(5) 1425-1431
    CrossrefPubMedGoogle Scholar
  • 9 Sehmi R, Wood L J, Watson R et al.. Allergen-induced increases in IL-5 receptor alpha-subunit expression on bone marrow-derived CD34+ cells from asthmatic subjects. A novel marker of progenitor cell commitment towards eosinophilic differentiation.  J Clin Invest. 1997;  100(10) 2466-2475
    PubMedGoogle Scholar
  • 10 Dorman S C, Sehmi R, Gauvreau G M et al.. Kinetics of bone marrow eosinophilopoiesis and associated cytokines after allergen inhalation.  Am J Respir Crit Care Med. 2004;  169(5) 565-572
    CrossrefPubMedGoogle Scholar
  • 11 Tavernier J, Van der H J, Verhee A et al.. Interleukin 5 regulates the isoform expression of its own receptor alpha-subunit.  Blood. 2000;  95(5) 1600-1607
    PubMedGoogle Scholar
  • 12 Leckie M J, ten Brinke A, Khan J et al.. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response.  Lancet. 2000;  356(9248) 2144-2148
    CrossrefPubMedGoogle Scholar
  • 13 Flood-Page P T, Menzies-Gow A N, Kay A B, Robinson D S. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway.  Am J Respir Crit Care Med. 2003;  167(2) 199-204
    CrossrefPubMedGoogle Scholar
  • 14 Gregory B, Kirchem A, Phipps S et al.. Differential regulation of human eosinophil IL-3, IL-5, and GM-CSF receptor alpha-chain expression by cytokines: IL-3, IL-5, and GM-CSF down-regulate IL-5 receptor alpha expression with loss of IL-5 responsiveness, but up-regulate IL-3 receptor alpha expression.  J Immunol. 2003;  170(11) 5359-5366
    PubMedGoogle Scholar
  • 15 Klion A D, Law M A, Noel P, Kim Y J, Haverty T P, Nutman T B. Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome.  Blood. 2004;  103(8) 2939-2941
    CrossrefPubMedGoogle Scholar
  • 16 Garrett J K, Jameson S C, Thomson B et al.. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes.  J Allergy Clin Immunol. 2004;  113(1) 115-119
    CrossrefPubMedGoogle Scholar
  • 17 Pardanani A, Reeder T, Porrata L F et al.. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders.  Blood. 2003;  101(9) 3391-3397
    CrossrefPubMedGoogle Scholar
  • 18 Gleich G J, Leiferman K M, Pardanani A, Tefferi A, Butterfield J H. Treatment of hypereosinophilic syndrome with imatinib mesilate.  Lancet. 2002;  359(9317) 1577-1578
    CrossrefPubMedGoogle Scholar
  • 19 Sehmi R, Dorman S, Baatjes A et al.. Allergen-induced fluctuation in CC chemokine receptor 3 expression on bone marrow CD34+ cells from asthmatic subjects: significance for mobilization of haemopoietic progenitor cells in allergic inflammation.  Immunology. 2003;  109(4) 536-546
    CrossrefPubMedGoogle Scholar
  • 20 Dorman S C, Efthimiadis A, Babirad I et al.. Sputum CD34+IL-5Ralpha+ cells increase after allergen: evidence for in situ eosinophilopoiesis.  Am J Respir Crit Care Med. 2004;  169(5) 573-577
    CrossrefPubMedGoogle Scholar
  • 21 Hakansson L, Carlson M, Stalenheim G, Venge P. Migratory responses of eosinophil and neutrophil granulocytes from patients with asthma.  J Allergy Clin Immunol. 1990;  85(4) 743-750
    CrossrefPubMedGoogle Scholar
  • 22 Luijk B, Lindemans C A, Kanters D et al.. Gradual increase in priming of human eosinophils during extravasation from peripheral blood to the airways in response to allergen challenge.  J Allergy Clin Immunol. 2005;  115(5) 997-1003
    CrossrefPubMedGoogle Scholar
  • 23 Warringa R A, Mengelers H J, Kuijper P H, Raaijmakers J A, Bruijnzeel P L, Koenderman L. In vivo priming of platelet-activating factor-induced eosinophil chemotaxis in allergic asthmatic individuals.  Blood. 1992;  79(7) 1836-1841
    PubMedGoogle Scholar
  • 24 Hakansson L, Venge P. Priming of eosinophil and neutrophil migratory responses by interleukin 3 and interleukin 5.  APMIS. 1994;  102(4) 308-316
    PubMedGoogle Scholar
  • 25 Sehmi R, Wardlaw A J, Cromwell O, Kurihara K, Waltmann P, Kay A B. Interleukin-5 selectively enhances the chemotactic response of eosinophils obtained from normal but not eosinophilic subjects.  Blood. 1992;  79(11) 2952-2959
    PubMedGoogle Scholar
  • 26 Hakansson L, Hoglund M, Jonsson U B, Torsteinsdottir I, Xu X, Venge P. Effects of in vivo administration of G-CSF on neutrophil and eosinophil adhesion.  Br J Haematol. 1997;  98(3) 603-611
    CrossrefPubMedGoogle Scholar
  • 27 Carlson M, Peterson C, Venge P. The influence of IL-3, IL-5, and GM-CSF on normal human eosinophil and neutrophil C3b-induced degranulation.  Allergy. 1993;  48(6) 437-442
    PubMedGoogle Scholar
  • 28 Burke-Gaffney A, Hellewell P G. Eotaxin stimulates eosinophil adhesion to human lung microvascular endothelial cells.  Biochem Biophys Res Commun. 1996;  227(1) 35-40
    CrossrefPubMedGoogle Scholar
  • 29 Gordon J R, Swystun V A, Li F et al.. Regular salbutamol use increases CXCL8 responses in asthma: relationship to the eosinophil response.  Eur Respir J. 2003;  22(1) 118-126
    CrossrefPubMedGoogle Scholar
  • 30 Carlson M, Peterson C, Venge P. The influence of IL-3, IL-5, and GM-CSF on normal human eosinophil and neutrophil C3b-induced degranulation.  Allergy. 1993;  48(6) 437-442
    PubMedGoogle Scholar
  • 31 Phillips R M, Stubbs V E, Henson M R, Williams T J, Pease J E, Sabroe I. Variations in eosinophil chemokine responses: an investigation of CCR1 and CCR3 function, expression in atopy, and identification of a functional CCR1 promoter.  J Immunol. 2003;  170(12) 6190-6201
    PubMedGoogle Scholar
  • 32 Schweizer R C, Welmers B A, Raaijmakers J A, Zanen P, Lammers J W, Koenderman L RA. RANTES- and interleukin-8 induced responses in normal human eosinophils: effects of priming with interleukin-5.  Blood. 1994;  83(12) 3697-3704
    PubMedGoogle Scholar
  • 33 Symon F A, Walsh G M, Watson S R, Wardlaw A J. Eosinophil adhesion to nasal polyp endothelium is P-selectin-dependent.  J Exp Med. 1994;  180(1) 371-376
    CrossrefPubMedGoogle Scholar
  • 34 del Pozo M A, Sanchez-Mateos P, Nieto M, Sanchez-Madrid F. Chemokines regulate cellular polarization and adhesion receptor redistribution during lymphocyte interaction with endothelium and extracellular matrix. Involvement of cAMP signaling pathway.  J Cell Biol. 1995;  131(2) 495-508
    CrossrefPubMedGoogle Scholar
  • 35 Finger E B, Bruehl R E, Bainton D F, Springer T A. A differential role for cell shape in neutrophil tethering and rolling on endothelial selectins under flow.  J Immunol. 1996;  157(11) 5085-5096
    PubMedGoogle Scholar
  • 36 Klion A D, Nutman T B. The role of eosinophils in host defense against helminth parasites.  J Allergy Clin Immunol. 2004;  113(1) 30-37
    CrossrefPubMedGoogle Scholar
  • 37 Kephart G M, Andrade Z A, Gleich G J. Localization of eosinophil major basic protein onto eggs of Schistosoma mansoni in human pathologic tissue.  Am J Pathol. 1988;  133(2) 389-396
    PubMedGoogle Scholar
  • 38 Glauert A M, Butterworth A E, Sturrock R F, Houba V. The mechanism of antibody-dependent, eosinophil-mediated damage to schistosomula of Schistosoma mansoni in vitro: a study by phase-contrast and electron microscopy.  J Cell Sci. 1978;  34 173-192
    PubMedGoogle Scholar
  • 39 Butterworth A E, Vadas M A, Wassom D L et al.. Interactions between human eosinophils and schistosomula of Schistosoma mansoni. II. The mechanism of irreversible eosinophil adherence.  J Exp Med. 1979;  150(6) 1456-1471
    CrossrefPubMedGoogle Scholar
  • 40 Abu-Ghazaleh R I, Gleich G J, Prendergast F G. Interaction of eosinophil granule major basic protein with synthetic lipid bilayers: a mechanism for toxicity.  J Membr Biol. 1992;  128(2) 153-164
    PubMedGoogle Scholar
  • 41 Kroegel C, Costabel U, Matthys H. Mechanism of membrane damage mediated by eosinophil major basic protein.  Lancet. 1987;  1(8546) 1380-1381
    PubMedGoogle Scholar
  • 42 Gleich G J, Frigas E, Loegering D A, Wassom D L, Steinmuller D. Cytotoxic properties of the eosinophil major basic protein.  J Immunol. 1979;  123(6) 2925-2927
    PubMedGoogle Scholar
  • 43 Arinaga S, Karimine N, Takamuku K et al.. Correlation of eosinophilia with clinical response in patients with advanced carcinoma treated with low-dose recombinant interleukin-2 and mitomycin C.  Cancer Immunol Immunother. 1992;  35(4) 246-250
    PubMedGoogle Scholar
  • 44 O'Donnell M C, Ackerman S J, Gleich G J, Thomas L L. Activation of basophil and mast cell histamine release by eosinophil granule major basic protein.  J Exp Med. 1983;  157(6) 1981-1991
    CrossrefPubMedGoogle Scholar
  • 45 Moy J N, Gleich G J, Thomas L L. Noncytotoxic activation of neutrophils by eosinophil granule major basic protein. Effect on superoxide anion generation and lysosomal enzyme release.  J Immunol. 1990;  145(8) 2626-2632
    PubMedGoogle Scholar
  • 46 Fryer A D, Costello R W, Yost B L et al.. Antibody to VLA-4, but not to L-selectin, protects neuronal M2 muscarinic receptors in antigen-challenged guinea pig airways.  J Clin Invest. 1997;  99(8) 2036-2044
    PubMedGoogle Scholar
  • 47 Rosenberg H F. The eosinophil ribonucleases.  Cell Mol Life Sci. 1998;  54(8) 795-803
    CrossrefPubMedGoogle Scholar
  • 48 Durack D T, Sumi S M, Klebanoff S J. Neurotoxicity of human eosinophils.  Proc Natl Acad Sci USA. 1979;  76(3) 1443-1447
    PubMedGoogle Scholar
  • 49 Durack D T, Ackerman S J, Loegering D A, Gleich G J. Purification of human eosinophil-derived neurotoxin.  Proc Natl Acad Sci USA. 1981;  78(8) 5165-5169
    PubMedGoogle Scholar
  • 50 Rosenberg H F, Domachowske J B. Eosinophils, eosinophil ribonucleases, and their role in host defense against respiratory virus pathogens.  J Leukoc Biol. 2001;  70(5) 691-698
    PubMedGoogle Scholar
  • 51 Newton D L, Rybak S M. Unique recombinant human ribonuclease and inhibition of Kaposi's sarcoma cell growth.  J Natl Cancer Inst. 1998;  90(23) 1787-1791
    CrossrefPubMedGoogle Scholar
  • 52 Harrison A M, Bonville C A, Rosenberg H F, Domachowske J B. Respiratory syncytial virus-induced chemokine expression in the lower airways: eosinophil recruitment and degranulation.  Am J Respir Crit Care Med. 1999;  159(6) 1918-1924
    PubMedGoogle Scholar
  • 53 Garofalo R, Kimpen J L, Welliver R C, Ogra P L. Eosinophil degranulation in the respiratory tract during naturally acquired respiratory syncytial virus infection.  J Pediatr. 1992;  120(1) 28-32
    PubMedGoogle Scholar
  • 54 Domachowske J B, Dyer K D, Bonville C A, Rosenberg H F. Recombinant human eosinophil-derived neurotoxin/RNase 2 functions as an effective antiviral agent against respiratory syncytial virus.  J Infect Dis. 1998;  177(6) 1458-1464
    PubMedGoogle Scholar
  • 55 Domachowske J B, Dyer K D, Adams A G, Leto T L, Rosenberg H F. Eosinophil cationic protein/RNase 3 is another RNase A-family ribonuclease with direct antiviral activity.  Nucleic Acids Res. 1998;  26(14) 3358-3363
    CrossrefPubMedGoogle Scholar
  • 56 Domachowske J B, Dyer K D, Adams A G, Leto T L, Rosenberg H F. Eosinophil cationic protein/RNase 3 is another RNase A-family ribonuclease with direct antiviral activity.  Nucleic Acids Res. 1998;  26(14) 3358-3363
    CrossrefPubMedGoogle Scholar
  • 57 Lacy P, Abdel-Latif D, Steward M, Musat-Marcu S, Man S F, Moqbel R. Divergence of mechanisms regulating respiratory burst in blood and sputum eosinophils and neutrophils from atopic subjects.  J Immunol. 2003;  170(5) 2670-2679
    PubMedGoogle Scholar
  • 58 Shult P A, Graziano F M, Wallow I H, Busse W W. Comparison of superoxide generation and luminol-dependent chemiluminescence with eosinophils and neutrophils from normal individuals.  J Lab Clin Med. 1985;  106(6) 638-645
    PubMedGoogle Scholar
  • 59 Schauer U, Leinhaas C, Jager R, Rieger C H. Enhanced superoxide generation by eosinophils from asthmatic children.  Int Arch Allergy Appl Immunol. 1991;  96(4) 317-321
    PubMedGoogle Scholar
  • 60 Jarjour N N, Busse W W, Calhoun W J. Enhanced production of oxygen radicals in nocturnal asthma.  Am Rev Respir Dis. 1992;  146(4) 905-911
    PubMedGoogle Scholar
  • 61 Antczak A, Nowak D, Shariati B, Krol M, Piasecka G, Kurmanowska Z. Increased hydrogen peroxide and thiobarbituric acid-reactive products in expired breath condensate of asthmatic patients.  Eur Respir J. 1997;  10(6) 1235-1241
    CrossrefPubMedGoogle Scholar
  • 62 Wedi B, Straede J, Wieland B, Kapp A. Eosinophil apoptosis is mediated by stimulators of cellular oxidative metabolisms and inhibited by antioxidants: involvement of a thiol-sensitive redox regulation in eosinophil cell death.  Blood. 1999;  94(7) 2365-2373
    PubMedGoogle Scholar
  • 63 Bandeira-Melo C, Weller P F. Eosinophils and cysteinyl leukotrienes.  Prostaglandins Leukot Essent Fatty Acids. 2003;  69(2-3) 135-143
    CrossrefPubMedGoogle Scholar
  • 64 Wenzel S E. The role of leukotrienes in asthma.  Prostaglandins Leukot Essent Fatty Acids. 2003;  69(2-3) 145-155
    CrossrefPubMedGoogle Scholar
  • 65 Cowburn A S, Sladek K, Soja J et al.. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma.  J Clin Invest. 1998;  101(4) 834-846
    PubMedGoogle Scholar
  • 66 Marom Z, Shelhamer J H, Bach M K, Morton D R, Kaliner M. Slow-reacting substances, leukotrienes C4 and D4, increase the release of mucus from human airways in vitro.  Am Rev Respir Dis. 1982;  126(3) 449-451
    PubMedGoogle Scholar
  • 67 Joris I, Majno G, Corey E J, Lewis R A. The mechanism of vascular leakage induced by leukotriene E4. Endothelial contraction.  Am J Pathol. 1987;  126(1) 19-24
    PubMedGoogle Scholar
  • 68 Adelroth E, Morris M M, Hargreave F E, O'Byrne P M. Airway responsiveness to leukotrienes C4 and D4 and to methacholine in patients with asthma and normal controls.  N Engl J Med. 1986;  315(8) 480-484
    PubMedGoogle Scholar
  • 69 Lee E, Robertson T, Smith J, Kilfeather S. Leukotriene receptor antagonists and synthesis inhibitors reverse survival in eosinophils of asthmatic individuals.  Am J Respir Crit Care Med. 2000;  161(6) 1881-1886
    PubMedGoogle Scholar
  • 70 Bandeira-Melo C, Sugiyama K, Woods L J, Weller P F. Cutting edge: eotaxin elicits rapid vesicular transport-mediated release of preformed IL-4 from human eosinophils.  J Immunol. 2001;  166(8) 4813-4817
    PubMedGoogle Scholar
  • 71 Bandeira-Melo C, Sugiyama K, Woods L J et al.. IL-16 promotes leukotriene C(4) and IL-4 release from human eosinophils via CD4- and autocrine CCR3-chemokine-mediated signaling.  J Immunol. 2002;  168(9) 4756-4763
    PubMedGoogle Scholar
  • 72 Bandeira-Melo C, Bozza P T, Weller P F. The cellular biology of eosinophil eicosanoid formation and function.  J Allergy Clin Immunol. 2002;  109(3) 393-400
    CrossrefPubMedGoogle Scholar
  • 73 Grewe M, Czech W, Morita A et al.. Human eosinophils produce biologically active IL-12: implications for control of T cell responses.  J Immunol. 1998;  161(1) 415-420
    PubMedGoogle Scholar
  • 74 Lamkhioued B, Gounni A S, Aldebert D et al.. Synthesis of type 1 (IFN gamma) and type 2 (IL-4, IL-5, and IL-10) cytokines by human eosinophils.  Ann NY Acad Sci. 1996;  796 203-208
    PubMedGoogle Scholar
  • 75 Moller G M, de Jong T A, van der Kwast T H et al.. Immunolocalization of interleukin-4 in eosinophils in the bronchial mucosa of atopic asthmatics.  Am J Respir Cell Mol Biol. 1996;  14(5) 439-443
    PubMedGoogle Scholar
  • 76 Moller G M, de Jong T A, Overbeek S E, van der Kwast T H, Postma D S, Hoogsteden H C. Ultrastructural immunogold localization of interleukin 5 to the crystalloid core compartment of eosinophil secondary granules in patients with atopic asthma.  J Histochem Cytochem. 1996;  44(1) 67-69
    PubMedGoogle Scholar
  • 77 Dubucquoi S, Desreumaux P, Janin A et al.. Interleukin 5 synthesis by eosinophils: association with granules and immunoglobulin-dependent secretion.  J Exp Med. 1994;  179(2) 703-708
    CrossrefPubMedGoogle Scholar
  • 78 Woerly G, Lacy P, Younes A B et al.. Human eosinophils express and release IL-13 following CD28-dependent activation.  J Leukoc Biol. 2002;  72(4) 769-779
    PubMedGoogle Scholar
  • 79 Schmid-Grendelmeier P, Altznauer F, Fischer B et al.. Eosinophils express functional IL-13 in eosinophilic inflammatory diseases.  J Immunol. 2002;  169(2) 1021-1027
    PubMedGoogle Scholar
  • 80 Moqbel R, Ying S, Barkans J et al.. Identification of messenger RNA for IL-4 in human eosinophils with granule localization and release of the translated product.  J Immunol. 1995;  155(10) 4939-4947
    PubMedGoogle Scholar
  • 81 Nakajima H, Gleich G J, Kita H. Constitutive production of IL-4 and IL-10 and stimulated production of IL-8 by normal peripheral blood eosinophils.  J Immunol. 1996;  156(12) 4859-4866
    PubMedGoogle Scholar
  • 82 Kita H, Ohnishi T, Okubo Y, Weiler D, Abrams J S, Gleich G J. Granulocyte/macrophage colony-stimulating factor and interleukin 3 release from human peripheral blood eosinophils and neutrophils.  J Exp Med. 1991;  174(3) 745-748
    CrossrefPubMedGoogle Scholar
  • 83 Hamid Q, Barkans J, Meng Q et al.. Human eosinophils synthesize and secrete interleukin-6, in vitro.  Blood. 1992;  80(6) 1496-1501
    PubMedGoogle Scholar
  • 84 Braun R K, Franchini M, Erard F et al.. Human peripheral blood eosinophils produce and release interleukin-8 on stimulation with calcium ionophore.  Eur J Immunol. 1993;  23(4) 956-960
    PubMedGoogle Scholar
  • 85 Costa J J, Matossian K, Resnick M B et al.. Human eosinophils can express the cytokines tumor necrosis factor-alpha and macrophage inflammatory protein-1 alpha.  J Clin Invest. 1993;  91(6) 2673-2684
    PubMedGoogle Scholar
  • 86 Lacy P, Mahmudi-Azer S, Bablitz B et al.. Rapid mobilization of intracellularly stored RANTES in response to interferon-gamma in human eosinophils.  Blood. 1999;  94(1) 23-32
    PubMedGoogle Scholar
  • 87 Nakajima T, Yamada H, Iikura M et al.. Intracellular localization and release of eotaxin from normal eosinophils.  FEBS Lett. 1998;  434(3) 226-230
    CrossrefPubMedGoogle Scholar
  • 88 Hartman M, Piliponsky A M, Temkin V, Levi-Schaffer F. Human peripheral blood eosinophils express stem cell factor.  Blood. 2001;  97(4) 1086-1091
    CrossrefPubMedGoogle Scholar
  • 89 Levi-Schaffer F, Temkin V, Malamud V, Feld S, Zilberman Y. Mast cells enhance eosinophil survival in vitro: role of TNF-alpha and granulocyte-macrophage colony-stimulating factor.  J Immunol. 1998;  160(11) 5554-5562
    PubMedGoogle Scholar
  • 90 Smith S J, Levi-Schaffer F. Mast cell-eosinophil-fibroblast crosstalk in allergic inflammation.  Chem Immunol. 2000;  78 81-92
    PubMedGoogle Scholar
  • 91 Levi-Schaffer F, Temkin V, Malamud V, Feld S, Zilberman Y. Mast cells enhance eosinophil survival in vitro: role of TNF-alpha and granulocyte-macrophage colony-stimulating factor.  J Immunol. 1998;  160(11) 5554-5562
    PubMedGoogle Scholar
  • 92 Shi H Z. Eosinophils function as antigen-presenting cells.  J Leukoc Biol. 2004;  76(3) 520-527
    CrossrefPubMedGoogle Scholar
  • 93 Noguchi H, Kephart G M, Colby T V, Gleich G J. Tissue eosinophilia and eosinophil degranulation in syndromes associated with fibrosis.  Am J Pathol. 1992;  140(2) 521-528
    PubMedGoogle Scholar
  • 94 Cho J Y, Miller M, Baek K J et al.. Inhibition of airway remodeling in IL-5-deficient mice.  J Clin Invest. 2004;  113(4) 551-560
    CrossrefPubMedGoogle Scholar
  • 95 Flood-Page P, Menzies-Gow A, Phipps S et al.. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics.  J Clin Invest. 2003;  112(7) 1029-1036
    CrossrefPubMedGoogle Scholar
  • 96 Hernnas J, Sarnstrand B, Lindroth P, Peterson C G, Venge P, Malmstrom A. Eosinophil cationic protein alters proteoglycan metabolism in human lung fibroblast cultures.  Eur J Cell Biol. 1992;  59(2) 352-363
    PubMedGoogle Scholar
  • 97 Powell P P, Klagsbrun M, Abraham J A, Jones R C. Eosinophils expressing heparin-binding EGF-like growth factor mRNA localize around lung microvessels in pulmonary hypertension.  Am J Pathol. 1993;  143(3) 784-793
    PubMedGoogle Scholar
  • 98 Solomon A, Aloe L, Pe'er J et al.. Nerve growth factor is preformed in and activates human peripheral blood eosinophils.  J Allergy Clin Immunol. 1998;  102(3) 454-460
    CrossrefPubMedGoogle Scholar
  • 99 Wong D T, Elovic A, Matossian K et al.. Eosinophils from patients with blood eosinophilia express transforming growth factor beta 1.  Blood. 1991;  78(10) 2702-2707
    PubMedGoogle Scholar
  • 100 Wong D T, Weller P F, Galli S J et al.. Human eosinophils express transforming growth factor alpha.  J Exp Med. 1990;  172(3) 673-681
    CrossrefPubMedGoogle Scholar
  • 101 Moqbel R, Ying S, Barkans J et al.. Identification of messenger RNA for IL-4 in human eosinophils with granule localization and release of the translated product.  J Immunol. 1995;  155(10) 4939-4947
    PubMedGoogle Scholar
  • 102 Hogan S P, Matthaei K I, Young J M, Koskinen A, Young I G, Foster P S. A novel T cell-regulated mechanism modulating allergen-induced airways hyperreactivity in BALB/c mice independently of IL-4 and IL-5.  J Immunol. 1998;  161(3) 1501-1509
    PubMedGoogle Scholar
  • 103 Cohn L, Tepper J S, Bottomly K. IL-4-independent induction of airway hyperresponsiveness by Th2, but not Th1, cells.  J Immunol. 1998;  161(8) 3813-3816
    PubMedGoogle Scholar
  • 104 Wills-Karp M, Luyimbazi J, Xu X et al.. Interleukin-13: central mediator of allergic asthma.  Science. 1998;  282(5397) 2258-2261
    CrossrefPubMedGoogle Scholar
  • 105 Grunig G, Warnock M, Wakil A E et al.. Requirement for IL-13 independently of IL-4 in experimental asthma.  Science. 1998;  282(5397) 2261-2263
    CrossrefPubMedGoogle Scholar
  • 106 Zhu Z, Homer R J, Wang Z et al.. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production.  J Clin Invest. 1999;  103(6) 779-788
    PubMedGoogle Scholar
  • 107 Chiaramonte M G, Donaldson D D, Cheever A W, Wynn T A. An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response.  J Clin Invest. 1999;  104(6) 777-785
    CrossrefPubMedGoogle Scholar
  • 108 Temkin V, Aingorn H, Puxeddu I et al.. Eosinophil major basic protein: first identified natural heparinase-inhibiting protein.  J Allergy Clin Immunol. 2004;  113(4) 703-709
    CrossrefPubMedGoogle Scholar
  • 109 McDonald D M. Angiogenesis and remodeling of airway vasculature in chronic inflammation.  Am J Respir Crit Care Med. 2001;  164(10 Pt 2) S39-S45
    CrossrefPubMedGoogle Scholar
  • 110 Lee C G, Link H, Baluk P et al.. Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung.  Nat Med. 2004;  10(10) 1095-1103
    CrossrefPubMedGoogle Scholar
  • 111 Hoshino M, Takahashi M, Aoike N. Expression of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin immunoreactivity in asthmatic airways and its relationship to angiogenesis.  J Allergy Clin Immunol. 2001;  107(2) 295-301
    CrossrefPubMedGoogle Scholar
  • 112 Karawajczyk M, Seveus L, Garcia R et al.. Piecemeal degranulation of peripheral blood eosinophils: a study of allergic subjects during and out of the pollen season.  Am J Respir Cell Mol Biol. 2000;  23(4) 521-529
    PubMedGoogle Scholar
  • 113 Sutton R B, Fasshauer D, Jahn R, Brunger A T. Crystal structure of a SNARE complex involved in synaptic exocytosis at 2.4 A resolution.  Nature. 1998;  395(6700) 347-353
    CrossrefPubMedGoogle Scholar
  • 114 Hoffmann H J, Bjerke T, Karawajczyk M, Dahl R, Knepper M A, Nielsen S. SNARE proteins are critical for regulated exocytosis of ECP from human eosinophils.  Biochem Biophys Res Commun. 2001;  282(1) 194-199
    CrossrefPubMedGoogle Scholar
  • 115 Moqbel R, Lacy P. Exocytotic events in eosinophils and mast cells.  Clin Exp Allergy. 1999;  29(8) 1017-1022
    CrossrefPubMedGoogle Scholar
  • 116 Filley W V, Holley K E, Kephart G M, Gleich G J. Identification by immunofluorescence of eosinophil granule major basic protein in lung tissues of patients with bronchial asthma.  Lancet. 1982;  2(8288) 11-16
    PubMedGoogle Scholar
  • 117 Woolley K L, Gibson P G, Carty K, Wilson A J, Twaddell S H, Woolley M J. Eosinophil apoptosis and the resolution of airway inflammation in asthma.  Am J Respir Crit Care Med. 1996;  154(1) 237-243
    PubMedGoogle Scholar
  • 118 Kankaanranta H, Lindsay M A, Giembycz M A, Zhang X, Moilanen E, Barnes P J. Delayed eosinophil apoptosis in asthma.  J Allergy Clin Immunol. 2000;  106(1 Pt 1) 77-83
    CrossrefPubMedGoogle Scholar
  • 119 Woolley K L, Gibson P G, Carty K, Wilson A J, Twaddell S H, Woolley M J. Eosinophil apoptosis and the resolution of airway inflammation in asthma.  Am J Respir Crit Care Med. 1996;  154(1) 237-243
    PubMedGoogle Scholar
  • 120 Sexton D W, Blaylock M G, Walsh G M. Human alveolar epithelial cells engulf apoptotic eosinophils by means of integrin- and phosphatidylserine receptor-dependent mechanisms: a process upregulated by dexamethasone.  J Allergy Clin Immunol. 2001;  108(6) 962-969
    CrossrefPubMedGoogle Scholar
  • 121 Uller L, Persson C G, Kallstrom L, Erjefalt J S. Lung tissue eosinophils may be cleared through luminal entry rather than apoptosis: effects of steroid treatment.  Am J Respir Crit Care Med. 2001;  164(10 Pt 1) 1948-1956
    PubMedGoogle Scholar
  • 122 Yamaguchi Y, Suda T, Ohta S, Tominaga K, Miura Y, Kasahara T. Analysis of the survival of mature human eosinophils: interleukin-5 prevents apoptosis in mature human eosinophils.  Blood. 1991;  78(10) 2542-2547
    PubMedGoogle Scholar
  • 123 Dewson G, Cohen G M, Wardlaw A J. Interleukin-5 inhibits translocation of Bax to the mitochondria, cytochrome c release, and activation of caspases in human eosinophils.  Blood. 2001;  98(7) 2239-2247
    CrossrefPubMedGoogle Scholar
  • 124 Nutku E, Aizawa H, Hudson S A, Bochner B S. Ligation of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis.  Blood. 2003;  101(12) 5014-5020
    CrossrefPubMedGoogle Scholar

Douglas S RobinsonM.D. 

Allergy and Clinical Immunology, National Heart and Lung Institute, and Leukocyte Biology Section, Faculty of Medicine, Imperial College London

Sir Alexander Fleming Building, Exhibition Road, London SW7 2AZ, UK

Email: d.s.robinson@imperial.ac.uk

      >